Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May:167:81-91.
doi: 10.1016/j.ejca.2022.03.005. Epub 2022 Mar 18.

Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study

Maria V Dieci  1 , Giuseppe Azzarello  2 , Vittorina Zagonel  3 , Franco Bassan  4 , Stefania Gori  5 , Giuseppe Aprile  6 , Vanna Chiarion-Sileni  7 , Sara Lonardi  3 , Cristina Oliani  8 , Marta Zaninelli  9 , Rita Chiari  10 , Adolfo Favaretto  11 , Alberto Pavan  12 , Elisabetta Di Liso  13 , Eleonora Mioranza  13 , Alessandra Baldoni  2 , Francesca Bergamo  3 , Marco Maruzzo  3 , Stamatia Ziampiri  4 , Alessandro Inno  5 , Filomena Graziani  6 , Giusy Sinigaglia  8 , Michele Celestino  13 , Pierfranco Conte  14 , Valentina Guarneri  14 ; Veneto Oncology Network
Affiliations

Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study

Maria V Dieci et al. Eur J Cancer. 2022 May.

Abstract

Introduction: We analyzed a cohort of patients with cancer and Sars-Cov-2 infection from the Veneto Oncology Network registry across two pandemic time periods.

Materials and methods: 761 patients with cancer and SARS-CoV-2 infection were included.

Results: 198 patients were diagnosed during the first pandemic time period (TP1; February 2020 September 2020), 494 during TP2 before the vaccination campaign (TP2/pre-vaccination; September 2020-21 February 2021) and 69 in TP2/post-vaccination (22 February 2021-15 May 2021). TP2 vs TP1 patients were younger (p = 0.004), showed more frequently a good performance status (p < 0.001) and <2 comorbidities (p = 0.002), were more likely to be on active anticancer therapy (p = 0.006). Significantly fewer patients in TP2 (3-4%) vs TP1 (22%) had an in-hospital potential source of infection (p < 0.001). TP2 patients were more frequently asymptomatic (p = 0.003). Significantly fewer patients from TP2 were hospitalized (p < 0.001) or admitted to intensive care unit (p = 0.006). All-cause mortality decreased from 30.3% in TP1, to 8.9% and 8.7% in the two TP2 periods (p < 0.001), reflected by a significant reduction in Sars-Cov-2-related mortality (15.2%, 7.5% and 5.8% in the three consecutive time periods, p = 0.004).

Conclusions: Differences in clinical characteristics and features of Sars-Cov-2 infection between TP1 and TP2 reflect the effects of protective measures and increased testing capacity. The lower mortality in TP2 is in line with a less frail population. However, the vast majority of death events in TP2 were related to COVID-19, reinforcing the priority to protect cancer patients.

Keywords: COVID-19; Cancer; Sars-Cov-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Number of new weekly cases of cancer patients diagnosed with Sars-Cov-2 infection across centres participating to the ROVID study from February 2020 to May 2021. Relevant time periods considered in the present study are shown.
Fig. 2
Fig. 2
Characteristics of Sars-Cov-2 infection across pandemic time periods: type of contact (A), symptoms (B–F), hospitalization and ICU admission (G), and COVID-19 therapies. ICU: intensive care unit.
Fig. 3
Fig. 3
Mortality rates across the three pandemic time periods.
See this image and copyright information in PMC

References

    1. https://covid19.who.int/
    1. https://opendatadpc.maps.arcgis.com/apps/dashboards/b0c68bce2cce478eaac8...
    1. https://salute.regione.veneto.it/c/document_library/get_file?uuid=ce0e02...
    1. Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C., Bria E., Brighenti M., Cadranel J., De Toma A., Chini C., Cortellini A., Felip E., Finocchiaro G., Garrido P., Genova C., Giusti R., Gregorc V., Grossi F., Grosso F., Intagliata S., La Verde N., Liu S.V., Mazieres J., Mercadante E., Michielin O., Minuti G., Moro-Sibilot D., Pasello G., Passaro A., Scotti V., Solli P., Stroppa E., Tiseo M., Viscardi G., Voltolini L., Wu Y.L., Zai S., Pancaldi V., Dingemans A.M., Van Meerbeeck J., Barlesi F., Wakelee H., Peters S., Horn L. TERAVOLT investigators. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020 Jul;21(7):914–922. doi: 10.1016/S1470-2045(20)30314-4. Epub 2020 Jun 12. PMID: 32539942; PMCID: PMC7292610. - DOI - PMC - PubMed
    1. de Azambuja E., Brandão M., Wildiers H., Laenen A., Aspeslagh S., Fontaine C., Collignon J., Lybaert W., Verheezen J., Rutten A., Vuylsteke P., Goeminne J.C., Demey W., Van Beckhoven D., Deblonde J., Rottey S., Geukens T., Punie K., Bafort K., Belkhir L., Bossuyt N., Colombie V., Daubresse C., Dauby N., De Munter P., Delmarcelle D., Delvallee M., Demeester R., Delefortrie Q., Dugernier T., Holemans X., Louviaux I., Machurot P., Minette P., Mokrane S., Nachtergal C., Noirhomme S., Piérard D., Rossi C., Schirvel C., Sermijn E., Staelens F., Triest F., Van Beckhoven D., Van Goethem N., Van Praet J., Vanhoenacker A., Verstraete R., Willems E., Wyndham-Thomas C. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open. 2020 Sep;5(5) doi: 10.1136/esmoopen-2020-000947. PMID: 32978251; PMCID: PMC7520811. - DOI - PMC - PubMed

Publication types